People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aliada Therapeutics, Inc. | — | Biotechnology | Series B | $33.0M | $438.3M | 2021 |
| Athenen Therapeutics, Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.7M | 2019 |
Sari Epstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sari Epstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Adam Rosenberg | 1 | 6 |
| James Schneider | 1 | 5 |
| Aaron Bergener | 1 | 2 |
| Adam J. Rosenberg | 1 | 2 |
| Sarah Reed | 1 | 2 |
| Jim J. Sullivan | 1 | 1 |
| Joshua J. Resnick | 1 | 1 |
| Laura J. Tadvalkar | 1 | 1 |
| Marian J. Nakada | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.